Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL20853620 | 0.98 | ALDH1A1 (0.55) | ALDH1A1MAPTHDAC1HDAC3HDAC2 | |
| SCHEMBL246721 | 0.98 | ALDH1A1 (0.59) | ALDH1A1MAPTHDAC1HDAC3HDAC2 | |
| SCHEMBL8969604 | 0.96 | ALDH1A1 (0.57) | ALDH1A1MAPTHDAC1HDAC3HDAC2 | |
| SCHEMBL8968746 | 0.95 | ALDH1A1 (0.55) | ALDH1A1MAPTHDAC1HDAC3HDAC2 | |
| SCHEMBL5524297 | 0.95 | ALDH1A1 (0.55) | ALDH1A1MAPTHDAC1HDAC3HDAC2 | |
| SCHEMBL8968708 | 0.95 | ALDH1A1 (0.55) | ALDH1A1MAPTHDAC1HDAC3HDAC2 | |
| SCHEMBL8969890 | 0.95 | ALDH1A1 (0.55) | ALDH1A1MAPTHDAC1HDAC3HDAC2 | |
| SCHEMBL1607864 | 0.94 | ALDH1A1 (0.59) | ALDH1A1MAPTHDAC1HDAC3HDAC2 | |
| SCHEMBL1607516 | 0.93 | ALDH1A1 (0.57) | ALDH1A1MAPTHDAC1HDAC3HDAC2 | |
| SCHEMBL1607454 | 0.93 | ALDH1A1 (0.57) | ALDH1A1MAPTHDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4726304-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| EP-1276483-B1 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | BELLUS HEALTH INT LTD (CH) | 2009-09-02 | — | — | EP | claimed |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | claimed |
| JP-2003517458-A | — | — | 2003-05-27 | — | — | JP | claimed |
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | claimed |
| EP-1276483-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-01-22 | — | — | EP | claimed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | claimed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | claimed |
| WO-2000064420-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-11-02 | — | — | WO | claimed |
| US-20110281951-A1 | Compositions and methods for treating amyloidosis | BHI LIMITED PARTNERSHIP (CA) | 2011-11-17 | — | — | US | disclosed |
| EP-1276483-B1 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | BELLUS HEALTH INT LTD (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20090099100-A1 | Compositions and methods for treating amyloidosis | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20070224685-A1 | Reagent Containing Protease Reaction Promoter and/or Colorant Stabilizer | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1788081-A1 | REAGENT CONTAINING PROTEASE REACTION PROMOTER AND/OR COLORANT STABILIZER | Asahi Kasei Pharma Corporation (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20040198832-A1 | Compositions and methods for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-10-07 | — | — | US | disclosed |
| EP-1276483-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-01-22 | — | — | EP | disclosed |
| WO-2000064420-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099100-A1 | Compositions and methods for treating amyloidosis | TTR, SNCA, ARSA | ALDH1A1 1526/4885MAPT 223/4885HDAC1 2054/4885 |
| US-20110281951-A1 | Compositions and methods for treating amyloidosis | TTR, SNCA, ARSA | ALDH1A1 1526/4885MAPT 223/4885HDAC1 2054/4885 |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | ALDH1A1 3305/4885MAPT 10/4885HDAC1 4744/4885 |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | ALDH1A1 3305/4885MAPT 10/4885HDAC1 4744/4885 |
| US-20040198832-A1 | Compositions and methods for treating amyloidosis | TTR, APP, CRYAA | ALDH1A1 1199/4885MAPT 185/4885HDAC1 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.